Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-11-10
Based on 384 first isolates · MED-B · Febrile UTI / pyelonephritis · 2023-11-12 → 2024-11-10
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ceftriaxone 80 % (76 %–84 %)
Not covered: Enterococcus faecalis (9 %), Pseudomonas aeruginosa (5 %), Staphylococcus aureus (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
86 %
90 %
n = 29
nitrofurantoin NIT
trend · Escherichia coli not for this site
80 %
76 %
n = 29
ceftriaxone CRO
trend · Escherichia coli
80 %
79 %
n = 29
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
79 %
n = 29
mecillinam MEC
trend · Escherichia coli not for this site
79 %
79 %
n = 29
ciprofloxacin CIP
trend · Escherichia coli
76 %
76 %
n = 29
74 %
62 %
n = 29
trimethoprim TMP
trend · Escherichia coli not for this site
71 %
69 %
n = 29
49 %
34 %
n = 29
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
10 %
n = 29
4 %
7 %
n = 29
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 29

Most likely organisms for this profile

Escherichia coli
54 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Klebsiella oxytoca
5 %
Pseudomonas aeruginosa
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.